The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA), has recommended marketing authorisation for Novo Nordisk Fiasp (fast-acting insulin aspart) for use in the treatment of adults with Type 1 and Type 2 diabetes. The CHMP recommends Fiasp, the intended brand name for fast-acting insulin aspart, to be used as the bolus component of basal-bolus therapy in combination with basal insulin and for continuous subcutaneous insulin infusion via an insulin pump. Novo Nordisk has developed Fiasp as mealtime insulin with an earlier and greater glucose-lowering effect than NovoRapid (insulin aspart).
“We believe Fiasp provides an important evolution in mealtime insulin, which can address the unmet medical need for people requiring further improved blood glucose control around meals or flexibility of dosing,” says Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. Novo Nordisk expects to receive final marketing authorisation from the European Commission in the first quarter of 2017.
News items and features like this appear in the Desang Diabetes Magazine, our free-to-receive digital journal. We cover diabetes news, diabetes management equipment (diabetes kit) and news about food suitable for a diabetic diet. Go to the top of this page to sign up – we just need your email address.